Anat Ashkenazi, Eli Lilly CFO

Is Lil­ly plan­ning two brands for tirzepatide? CFO dis­cuss­es di­a­betes and obe­si­ty pos­si­bil­i­ties

Eli Lil­ly is ad­dress­ing the pos­si­bil­i­ty of two brand names for tirzepatide — again. The drug — which is al­ready ap­proved to treat type 2 di­a­betes as Moun­jaro — could be get­ting a dif­fer­ent brand name when, as an­tic­i­pat­ed, it gets ap­proved for an obe­si­ty in­di­ca­tion.

That’s a def­i­nite maybe or maybe not, in light of CFO Anat Ashke­nazi’s re­marks at the Mor­gan Stan­ley health­care con­fer­ence on Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.